Community Mental Health Center
Muş, Turkey (Türkiye)
Location status: Recruiting
NCT Number: NCT07144592
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.
The study will be conducted as a randomized controlled trial including 60 clinically stable individuals diagnosed with schizophrenia according to DSM-5 criteria and registered at a Community Mental Health Center affiliated with a university hospital. Participants will be randomly assigned to an experimental group (n=30) and a control group (n=30).
The experimental group will receive one individual solution-focused therapy session per week for six weeks. The control group will receive usual care only. Data will be collected using a Personal Information Form, the Psychosocial Adjustment Scale (PSSAS), and the Medication Adherence Scale (MARS).
Interested in participating?
Request Info18 year–65 year
All sexes
Interventional
Not applicable
Muş, Turkey (Türkiye)
Location status: Recruiting
Objective:
Schizophrenia is a chronic psychiatric disorder that significantly affects thought, emotion, and behavior, often limiting social functioning, treatment adherence, and integration into daily life. There is an increasing need for person-centered, empowering, and brief intervention models in psychiatric nursing. This study aims to determine the effects of a solution-focused approach (SFA)-based individual intervention on psychosocial adjustment and treatment adherence in individuals with schizophrenia.
Study Design:
This research will use a pretest-posttest randomized controlled experimental design with a control group.
Study Population:
The study will include 60 individuals diagnosed with schizophrenia according to DSM-5 diagnostic criteria, considered clinically stable, and registered at a Community Mental Health Center affiliated with a university hospital in Türkiye. Participants will be randomly assigned to an experimental group (n=30) or a control group (n=30) using computer-assisted randomization.
Intervention:
Experimental Group: Participants will receive individual solution-focused therapy sessions once per week for six consecutive weeks. The sessions will emphasize individual strengths, recall positive coping experiences, support future goal setting, and provide guidance on repeating effective solutions.
Control Group: Participants will receive no additional intervention beyond usual care.
Outcome Measures:
Data will be collected with the following instruments:
Personal Information Form
Psychosocial Adjustment Scale (PSSAS)
Medication Adherence Scale (MARS)
Statistical Analyses:
Planned analyses will include independent samples t-tests, paired t-tests, and ANCOVA.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Being between 18 and 65 years of age,
Being literate and verbally communicative,
Being clinically stable (not exhibiting symptoms of acute psychosis),
Being registered with a Community Mental Health Center (CMHC) and receiving regular services,
Being cognitively competent enough to participate in individual interviews during the research process,
Being an individual currently receiving psychiatric treatment and taking medication,
Agreeing to participate voluntarily in the study and signing a written informed consent form.
Exclusion criteria
The solution-focused nursing intervention applied to the experimental group in the study was planned as individual sessions, consisting of one session per week, lasting a total of six weeks. The interventions were based on the principles of solution-focused brief therapy, focusing on the individual's strengths, past coping experiences, and current resources. The interviews aimed to identify exceptions, build positive future expectations, set small but achievable goals, strengthen hope, and increase the individual's ability to utilize their internal resources. Each session used structured open-ended questions, scaling techniques, and future-oriented solution scenarios to support the individual's psychosocial adjustment and motivation for treatment.
Time frame: Baseline (1 week before intervention)]
Description: Measured with the Psychosocial Adjustment Scale (PSSAS), which assesses social relationships, daily life management, and coping with stress. Scores range from 0 to 180; higher scores indicate better psychosocial adjustment.
Time Frame: Baseline (within 1 week before intervention)
Unit of Measure: Total score (0-180)
Time frame: Baseline (within 1 week before intervention)
Description: Measured with the Medication Adherence Scale (MARS), which assesses adherence to prescribed pharmacological treatment. Scores range from 0 to 10; higher scores indicate better medication adherence.
Time Frame: Baseline (within 1 week before intervention)
Unit of Measure: Total score (0-10)
Time frame: 6 weeks after baseline (post-intervention)
Description: Psychosocial Adjustment Scale (PSSAS). Scores range from 0 to 180; higher scores indicate better psychosocial adjustment.
Time Frame: 6 weeks after baseline (post-intervention)
Unit of Measure: Total score (0-180)
Time frame: Post-intervention (6 weeks after completion of the intervention)
Description: Medication Adherence Scale (MARS). Scores range from 0 to 10; higher scores indicate better medication adherence.
Time Frame: Post-intervention (6 weeks after completion of the intervention)
Unit of Measure: Total score (0-10)
Contact information is provided by the study sponsor or research team.
Muş Alparslan University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07716969
Mental Disorders, Psychosis
Copenhagen, Denmark
View Trial DetailsNCT07559084
Mental Disorders, SCHIZOPHRENIA 1 (Disorder)
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07242586
Mental Disorders, Personality Disorders
Copenhagen, Denmark
View Trial DetailsNCT07190352
Mental Disorders, Nicotine Use
Boston, Massachusetts, United States
View Trial Details